THCBF - OTC
VANCOUVER, Aug. 11, 2017 /CNW/ - THC BioMed Intl Ltd ("THC" or the "Company") (CSE: THC) is pleased to announce that following a commitment with Alumina Partners (Ontario) Ltd. ("Alumina") for up to $12,000,000 (twelve million dollars), the Company has issued 483,870 units to Alumina (the "Units") at a price of $0.31 per Unit for gross proceeds of $150,000 (the "Private Placement") as part of the draw down facility. Each Unit consists of one common share ("Private Placement Share") and one common share purchase warrant ("Warrant"). Each whole Warrant entitles Alumina to purchase one common share of the Company for a period of 36 months from closing at a price of $0.3875 per common share. Proceeds will be used for business expansion, marketing and general working capital.
This financing has been structured to best suit the fast-growing Cannabis Industry. Alumina has structured the terms so that funds may be drawn on an as needed basis, allowing THC to finance as it achieves milestones on an upward trajectory.
"While growth is necessary in a fast-moving industry like we are witnessing, quick access to capital is essential. However, we continue to remain conscious of dilution and look towards revenue generation and profitability to finance our growth only using financing as a last resort", commented John Miller, THC Biomed President and CEO. "This is the second capital commitment we have entered into giving us access to $22 million dollars."
"We were impressed by THC Biomed's decisive execution on their corporate vision, quickly closing on their Clone Shipper acquisition while simultaneously laying the groundwork in preparation for becoming the wholesaler of choice of live clones to the expected home growers' market," said Adi Nahmani, Managing Member of Alumina Partners. "If realizing the potential in this new market revolves around taking calculated risks, we're eager to see what the future holds for THC."
THC's vision is to be on the leading edge of scientific research, development of products and services related to the medical cannabis industry while creating a standard of excellence. As the industry develops, it will become more important to focus on scientific research and development of products and services related to medical cannabis. Management believes THC is well-positioned to be in the forefront of this rapidly growing industry.
Please visit our website for a more detailed description of our business and services available. www.thcbiomed.com
The Canadian Securities Exchange (CSE) has not reviewed and does not accept responsibility for the adequacy or the accuracy of the contents of this release.
This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of THC. Forward-looking information is based on certain key expectations and assumptions made by the management of THC. Although THC believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because THC can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release and include that: (a) the investment from Alumina will be used as working capital and THC's ongoing activities; (b) THC's vision is to be on the leading edge of scientific research, development of products and services related to the medical cannabis industry while creating a standard of excellence; (c) as the medical marijuana industry develops, it will become more important to focus on scientific research and development of products and services related to medical cannabis; and (d) THC will be in the forefront of this rapidly growing industry.
THC disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
SOURCE THC BioMed
For further information: President and CEO: John Miller, THC Biomed Intl Ltd., T: 1-844-THCMEDS, E: [email protected]